Komori
Fuji Pharma (4554) · RiskRestated

Litigation Risks, Including Patent Infringement and Product Liability

First written in FY2017. 1 of 3 entries say "Mitigated", first in FY2021. Latest entry: FY2022.

3entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017MitigatedFY20212017: 12018: 020182019: 020192020: 020202021: 120212022: 12022
Same theme, other companies
Risk of Litigation and Business Restrictions Across Multiple Areas, Including Regulatory Violations, Intellectual Property and Product LiabilityA theme 37 companies write about · 37 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 4 of 8 companies on the "Worse" side.

22 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「As measures, the Intellectual Property Department checks potential patent-related litigation risks in advance, while the Legal Department checks regulatory-related risks, with both working to reduce the likelihood of these risks materializing.」

    Continues the measures under which the Intellectual Property Department and Legal Department conduct advance checks on patent and regulatory matters.
  2. FY2021MitigatedAnnual report

    「As measures, the Intellectual Property Department checks potential patent-related litigation risks in advance, while the Legal Department checks regulatory-related risks, with both working to reduce the likelihood of these risks materializing.」

    Describes advance checks by the Intellectual Property Department and Legal Department as specific measures against litigation risks, including patent infringement and product liability.
  3. FY2017First statedAnnual report

    「There is a possibility that new drug manufacturers may bring lawsuits alleging infringement of process patents or other patents. Lawsuits may also be brought in connection with product liability, environmental, labor, and other matters.」

    Describes the possibility of litigation involving patent infringement, product liability, environmental, labor, and other matters.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuji Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Litigation Risks, Including Patent Infringement and Product Liability | Fuji Pharma Co.,Ltd. (4554) | Komori